Skip to content
lifestyle.sli.mg
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SOLIGENIX, INC.
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet’s Disease
February 26, 2026
Soligenix to Present at BIO Investment & Growth Summit
February 24, 2026
Soligenix Details Recent Progress and Upcoming Milestones
February 12, 2026
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet’s Disease Published in Rheumatology (Oxford)
December 20, 2025
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
December 19, 2025
←
Previous Page
1
2